Canada NewsWire
Conference call to be conducted on November 19, 2020 at 11:00 am ET
QUEBEC CITY, Nov. 12, 2020 /CNW Telbec/ – OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company commercializing a second generation fiber optic pressure guidewire to diagnose and treat coronary disease, has scheduled a year-end update conference call on Thursday, November 19, 2020, at 11:00 am ET.
Interested parties can access the conference call by dialing (877) 270-2148 or (412) 902-6510 or can listen via a live Internet webcast, which is available in the Investors section of the Company’s website or at https://www.webcaster4.com/Webcast/Page/2512/38573.
A teleconference replay of the call will be available for three days at (877) 344-7529 or at (412) 317-0088, confirmation #10149692. A webcast replay will be available in the Investors section of the Company’s website or via https://www.webcaster4.com/Webcast/Page/2512/38573.
About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)
OpSens focuses mainly on coronary physiology products in interventional cardiology. OpSens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.
OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.
SOURCE OPSENS Inc.
